An American drug company is facing criticism from ophthalmologists for allegedly denying the legitimate use of a cheap and effective treatment for macular degeneration, in favour of a more expensive drug.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here